|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study显示文摘 | William C Huang Andrew S Levey Angel M Serio Mark Snyder Andrew J Vickers Ganesh V Raj Peter T Scardino Paul Russo | 2006 | Lancet Oncology2006，，9： | 4 |
| 2 | Ability of bone graft substitutes to support the osteoprogenitor cells: An in-vitro study显示文摘AIM: To compare seven commercially available bone graft substitutes(BGS) in terms of these properties and without using any additional biological growth factors.METHODS: Porcine osteoprogenitor cells were loaded on seven commercially available BGS and allowed to proliferate for one week followed by osteogenic induction. Staining for live/dead cells as well as scanning electron microscopy(SEM) was carried out to determine viability and cellular binding. Further outcome measures included alkaline phosphatase(ALP) assays with normalisation for DNA content to quantify osteogenic potential. Negative and positive control experiments were carried out in parallel to validate the results.RESULTS: Live/dead and SEM imaging showed higher viability and attachment with β-tricalcium phosphate(β-TCP) than with other BGS(P < 0.05). The average ALP activity in nmol/mL(normalised value for DNA content in nmol/μg DNA) per sample was 657.58(132.03) for β-TCP, 36.22(unable to normalise) for calcium sulphate, 19.93(11.39) for the Hydroxyapatite/Tricalcium Phosphate composite, 14.79(18.53) for polygraft, 13.98(8.15) for the highly porous β-Tricalcium Phosphate, 5.56(10.0) for polymers, and 3.82(3.8) for Hydroxyapatite.CONCLUSION: Under the above experimental conditions, β-TCP was able to maintain better the viability of osteoprogenitor cells and allow proliferation and differentiation(P < 0.05). | Ziad Dahabreh Michalis Panteli Ippokratis Pountos Mark Howard Peter Campbell Peter V Giannoudis | 2014 | World Journal of Stem Cells2014，6，4： | 3 |
| 3 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 4 | Self-expanding metal stent for complicated and recurrent esophagogastric cancer显示文摘 | Peter DS Saskia L S Mark V B | | 0，，： | 1 |
| 5 | Reburning chemistry-mixing model 显示文摘 | Vitali V L Vladimir M Z Peter M M Mark S S | 2001 | Combustion and Flame2001，125，： | 1 |
| 6 | Ca^sup 2+^/calmodulin-dependent kinase II triggers cell membrane injury by inducing complement factor B gene expression in the mouse heart显示文摘 | Singh Madhu V Kapoun Ann Higgins Linda Kutschke William Thurman Joshua M Zhang Rong Singh Minati Yang Jinying Guan Xiaoqun Lowe John S Weiss Robert M Zimmermann Kathy Yull Fiona E Blackwell Timothy S Mohler Peter J Anderson Mark E | 2009 | Journal of Clinical Investigation2009，，4： | 1 |
| 7 | A new design metal stent (Flamingo stent) for palliation of malignant dysphagia:a prospective study 显示文摘 | PETER D S WIN C J H MARK V B | 2000 | Gastrointest Endos2000，51，： | 1 |
| 8 | High dose rate brachytherapy for the palliation of malignant dysphagia显示文摘 | Marjolein Y.V. Homs Wilhelmina M.H. Eijkenboom Véronique L.M.A. Coen Jelle Haringsma Mark van Blankenstein Ernst J. Kuipers Peter D. Siersema | 2003 | Radiotherapy and Oncology2003，，3： | 1 |
| 9 | Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study显示文摘 | William C Huang Andrew S Levey Angel M Serio Mark Snyder Andrew J Vickers Ganesh V Raj Peter T Scardino Paul Russo | 2006 | Lancet Oncology2006，，9： | 1 |
| 10 | Motivating knowledge sharing through a knowledge management system 显示文摘 | William R K Peter V Marks J | 2008 | Omega2008，36，： | 1 |
| 11 | Predicting plant species responses to grazing显示文摘 | Peter A V Mark W | 2001 | Journal of Applied Ecology2001，38，5： | 1 |
| 12 | Motivating knowledge shar- ing through a knowledge management system 显示文摘 | William R King Peter V Marks | 2008 | OMEGA2008，36，1： | 1 |
| 13 | The most important issues in knowledge management显示文摘 | WILLIAM R KING PETER V MARKS JR | 2002 | COMMUNICATIONS OF THE ACM2002，45，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员